{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:52:05Z","timestamp":1793404325632,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002352","name":"Ain Shams University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002352","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ital J Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Micafungin, Amphotericin B, and Fluconazole are the primary therapeutic agents employed to address invasive fungal candidiasis in neonates. Resistance to fluconazole is gradually developing in neonatal intensive care units. We aimed to conduct a comparative analysis of Micafungin and Amphotericin B in terms of their effectiveness and safety in the treatment of invasive fungal infections in neonates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Fifty-six preterm neonates with invasive fungal infection proven by fungal culture and who had received fluconazole for at least one week were included in our study and were divided randomly into two groups. Micafungin group: twenty-eight preterms received Micafungin at a dose of 8\u00a0mg\/kg\/day for 14 days. Amphotericin B group: twenty-eight preterms received amphotericin B at a dose of 1\u00a0mg \/kg\/day for 14 days. Clinical and laboratory follow up by fungal culture were performed after 14 days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Neonates in the Micafungin group showed significant increased percentage for complete cure of the fungal infection compared to Amphotericin B group 18(64.3%) vs. 10(35.7%) respectively and decreased percentage of incomplete cure 10(35.7%) vs. 18(64.3%) respectively with\n                      <jats:italic>p<\/jats:italic>\n                      -value 0.030. A higher percentage of neonates were completely cured for both candida albicans (65.2%) and non-albicans (60%) in the micafungin group. Duration of respiratory and circulatory support was significantly shorter also. No additional drug side effects were observed with Micafungin except for mild hypomagnesemia. There was an increase in blood urea nitrogen with Amphotericin B.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Micafungin is effective and well tolerated for the treatment of invasive fungal infections in preterm neonates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      The current study was approved by clinicaltrials.org and the protocol ID NCT06413056 was retrospectively registered in on 11th of march 2024.\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT06413056?cond=micafungin%20in%20neonates&amp;rank=2\" ext-link-type=\"uri\">https:\/\/clinicaltrials.gov\/study\/NCT06413056?cond=micafungin%20in%20neonates&amp;rank=2<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13052-025-01852-9","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T07:38:29Z","timestamp":1740728309000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Micafungin versus Amphotericin B in treatment of invasive fungal infection in preterm neonates: a randomized control trial"],"prefix":"10.1186","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4936-8303","authenticated-orcid":false,"given":"Mariam John Amin","family":"Ibrahim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa Saad","family":"Mohammed Fathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mertte Ashraf Thabet","family":"Ghobrial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7353-9857","authenticated-orcid":false,"given":"Maha Hassan","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"issue":"2","key":"1852_CR1","first-page":"50","volume":"3","author":"K - Arikan","year":"2021","unstructured":"Arikan K, Oguz HK, Sebnem C, Aybuke AK, Nuri B, Ilker D, et al. Safety and Effectiveness of Micafungin in neonates: a Retrospective Analytical Study from a Tertiary Pediatric Center. Annals Neonatology J. 2021;3(2):50\u201369.","journal-title":"Annals Neonatology J"},{"issue":"12","key":"1852_CR2","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1093\/cid\/ciab025","volume":"73","author":"G - Taormina","year":"2021","unstructured":"Taormina G, Gopinath R, Moore J, Yasinskaya Y, Colangelo P, Reynolds K, Nambiar S. A regulatory review approach for evaluation of micafungin for treatment of neonatal candidiasis. Clin Infect Dis. 2021;73(12):2335\u201340.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"1852_CR3","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1111\/bcp.13628","volume":"84","author":"S - Leroux","year":"2018","unstructured":"Leroux S, Jacqz-Aigrain E, Elie V, Legrand F, Barin\u2010Le Guellec C, Aurich B. FP7 TINN (treat infections in NeoNates) consortium. Pharmacokinetics and safety of fluconazole and micafungin in neonates with systemic candidiasis: a randomized, open\u2010label clinical trial. Br J Clin Pharmacol. 2018;84(9):1989\u201399.","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"1852_CR4","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1097\/00006454-200112000-00005","volume":"20","author":"L - Saiman","year":"2001","unstructured":"Saiman L, Ludington E, Dawson JD. Risk factors for candida species colonization of neonatal intensive care unit patients. Pediatr Infect Dis J. 2001;20(12):1119\u201324.","journal-title":"Pediatr Infect Dis J"},{"issue":"12","key":"1852_CR5","doi-asserted-by":"publisher","first-page":"7333","DOI":"10.1128\/AAC.01172-16","volume":"60","author":"C - Auriti","year":"2016","unstructured":"Auriti C, Falcone M, Ronchetti MP, Goffredo BM, Cairoli S, Crisafulli R, et al. High-dose micafungin for preterm neonates and infants with invasive and central nervous system candidiasis. Antimicrob Agents Chemother. 2016;60(12):7333\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"1852_CR6","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.ijantimicag.2019.02.019","volume":"53","author":"YH Chen","year":"2019","unstructured":"Chen YH, Cheng IL, Lai CC. Echinocandins VS. amphotericin B against invasive candidiasis in children and neonates: a meta-analysis of randomized controlled trails. Int J Antimicrob Agents. 2019;53(6):789\u201394.","journal-title":"Int J Antimicrob Agents"},{"key":"1852_CR7","doi-asserted-by":"crossref","unstructured":"DenningDW. MarrKA,LauWM : Micagungin alone or in combination with other systemic antifungal agents for treatment of acute invasive aspergillosis; 2006;53(5):337\u201349.","DOI":"10.1016\/j.jinf.2006.03.003"},{"issue":"5","key":"1852_CR8","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1111\/bcp.13521","volume":"84","author":"EC - Andrew","year":"2018","unstructured":"Andrew EC, Curtis N, Coghlan B, et al. ,:adverse effects of amphotericin B in children:a retrospective comparison of conventional and liposomal formulations. Br J clin Pharmacol. 2018;84(5):1006\u201312.","journal-title":"Br J clin Pharmacol"},{"issue":"12","key":"1852_CR9","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1097\/INF.0b013e3182737427","volume":"31","author":"WJ - Steinbach","year":"2012","unstructured":"Steinbach WJ, Roilides E, Berman D, Hoffman JA, Groll AH, Bin-Hussain I, Zaoutis TE. Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates. Pediatr Infect Dis J. 2012;31(12):1252\u20137.","journal-title":"Pediatr Infect Dis J"},{"key":"1852_CR10","doi-asserted-by":"crossref","unstructured":"Viscoli C, Bassetti M, Castagnola E, Cesaro S, Menichetti F, Ratto S, Giacobbe DR. Micafungin for the treatment of proven and suspected invasive candidiasis in children and adults: findings from a multicenter prospective observational study. BMC Infect Dis; 2014;14(1):1\u20137.","DOI":"10.1186\/s12879-014-0725-7"},{"issue":"9","key":"1852_CR11","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1097\/INF.0b013e31817275e6","volume":"27","author":"F Queiroz-Telles","year":"2008","unstructured":"Queiroz-Telles F, Berezin E, Leverger G, Freire A, van der Vyver A, Chotpitayasunondh T, Micafungin Invasive Candidiasis Study Group. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J. 2008;27(9):820\u20136.","journal-title":"Pediatr Infect Dis J"},{"issue":"10","key":"1852_CR12","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1097\/INF.0000000000001996","volume":"37","author":"DK - Benjamin Jr","year":"2018","unstructured":"Benjamin DK Jr, Kaufman DA, Hope WW, Smith PB, Arrieta A, Manzoni P, Walsh TJ. A phase 3 study of micafungin versus amphotericin B deoxycholate in infants with invasive candidiasis. Pediatr Infect Dis J. 2018;37(10):992.","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"1852_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13054-018-2019-8","volume":"22","author":"E - Maseda","year":"2018","unstructured":"Maseda E, Grau S, Luque S, Castillo-Mafla MP, Su\u00e1rez-de-la-Rica A, Montero-Feijoo A, Roberts JA. Population pharmacokinetics\/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients. Crit Care. 2018;22(1):1\u20139.","journal-title":"Crit Care"},{"issue":"2","key":"1852_CR14","doi-asserted-by":"publisher","first-page":"F127","DOI":"10.1136\/fnn.2006.097758","volume":"92","author":"L - Clerihew","year":"2007","unstructured":"Clerihew L, Lamagni TL, Brocklehurst P, McGuire W. Candida parapsilosis infection in very low birthweight infants. Arch Dis Child Fetal Neonatal Ed. 2007;92(2):F127.","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"1","key":"1852_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13052-017-0332-5","volume":"43","author":"C - Garzillo","year":"2017","unstructured":"Garzillo C, Bagattini M, Bogdanovi\u0107 L, Di Popolo A, Iula VD, Catania MR, Zarrilli R. Risk factors for Candida parapsilosis bloodstream infection in a neonatal intensive care unit: a case-control study. Ital J Pediatr. 2017;43(1):1\u20139.","journal-title":"Ital J Pediatr"},{"issue":"4","key":"1852_CR16","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/civ933","volume":"62","author":"PG - Pappas","year":"2016","unstructured":"Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Sobel JD. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1\u201350.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"1852_CR17","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.clp.2021.03.011","volume":"48","author":"J - Johnson","year":"2021","unstructured":"Johnson J, Akinboyo IC, Schaffzin JK. Infection Prevention in the neonatal Intensive Care Unit. Clin Perinatol. 2021;48(2):413\u201329. https:\/\/doi.org\/10.1016\/j.clp.2021.03.011. PMID: 34030822; PMCID: PMC8162277.","journal-title":"Clin Perinatol"},{"issue":"4","key":"1852_CR18","doi-asserted-by":"publisher","first-page":"718","DOI":"10.3390\/vaccines11040718","volume":"11","author":"C - Costantino","year":"2023","unstructured":"Costantino C, Conforto A, Bonaccorso N, Cimino L, Sciortino M, Palermo M, Maiolo K, Tina LG, Betta PM, Caracciolo M, Loretta CM, Arco A, Gitto E, Vitaliti SM, Mancuso D, Vitaliti G, Rosella V, Pinello G, Corsello G, Serra G, Gabriele B, Tramuto F, Restivo V, Amodio E, Vitale F. Safety of Rotavirus Vaccination in Preterm infants admitted in neonatal intensive care units in Sicily, Italy: a Multicenter Observational Study. Vaccines (Basel). 2023;11(4):718. https:\/\/doi.org\/10.3390\/vaccines11040718. PMID: 37112630; PMCID: PMC10145326.","journal-title":"Vaccines (Basel)"},{"key":"1852_CR19","unstructured":"Giordano S, Serra G, Dones P, Di Gangi M, Failla MC, Iaria C, Ricciardi F, Pernice LM, Pantaleo D, Cascio A. Acute pancreatitis in children and rotavirus infection. Description of a case and minireview. New Microbiol. 2013;36(1):97\u2013101. Epub 2013 Jan 1. PMID: 23435823."},{"issue":"2","key":"1852_CR20","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3390\/jof9020164","volume":"9","author":"G - Ferrando","year":"2023","unstructured":"Ferrando G, Castagnola E. Prophylaxis of Invasive Fungal infection in neonates: a narrative review for practical purposes. J Fungi (Basel). 2023;9(2):164. https:\/\/doi.org\/10.3390\/jof9020164. PMID: 36836279; PMCID: PMC9962596.","journal-title":"J Fungi (Basel)"}],"container-title":["Italian Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-025-01852-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13052-025-01852-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-025-01852-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T07:38:33Z","timestamp":1740728313000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijponline.biomedcentral.com\/articles\/10.1186\/s13052-025-01852-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1852"],"URL":"https:\/\/doi.org\/10.1186\/s13052-025-01852-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4421309\/v1","asserted-by":"object"}]},"ISSN":["1824-7288"],"issn-type":[{"value":"1824-7288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]},"assertion":[{"value":"21 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was done after approval from the Research Ethics Committee, Ain Shams University (number: M S 654\/2022). An informed written consent was taken from the parents or the legal guardians of the eligible neonates after explanation of the study and its aim. The included participants had the right to withdraw from the study at any time without giving any reasons. Data was collected confidentially and was only used for research purposes. All the authors approved the final manuscript as submitted and agreed to be accountable for all aspects of the work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable, personal data from the participants was not used in this study. Data collected was only related to the research aspects and not personal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"61"}}